The management of acute ischemic stroke during anticoagulation with a novel oral anticoagulant (NOAC) is challenging because intravenous thrombolysis is contraindicated because of a putative increased risk of intracerebral hemorrhagic complications. We examined the risk of secondary postischemic hemorrhage after thrombolysis in rodents pretreated with rivaroxaban or warfarin. Mice were pretreated with either rivaroxaban (30 mg/kg), warfarin (target international normalized ratio 2 to 3) or vehicle. After 2 or 3 hours, middle cerebral artery occlusion (MCAO), mice received 9 mg/kg recombinant tissue plasminogen activator. Twenty-four hours after MCAO, secondary hemorrhage was quantified using a macroscopic hemorrhage score and hemoglobin spectrophotometry. Blood-brain barrier (BBB) permeability was measured by Evans Blue spectrofluorometry. To increase the validity of our findings, experiments were also performed using a thromboembolic model in anticoagulated rats. Infarct size did not differ among groups. Pretreatment with warfarin led to significantly more secondary hemorrhage compared with rivaroxaban and nonanticoagulated controls after 2-and 3-hour ischemia in mice as well as in rats. Blood-brain barrier permeability was significantly higher in the warfarin group compared with rivaroxaban and control. Thus, rivaroxaban in contrast to warfarin does not increase secondary hemorrhage after thrombolysis in experimental cerebral ischemia. Less effects of rivaroxaban on postischemic BBB permeability may account for this difference.
INTRODUCTION
The recent introduction of direct thrombin (dabigatran) 1 and factor Xa inhibitors (rivaroxaban and apixaban) 2, 3 provides new opportunities for stroke prevention for millions of patients with atrial fibrillation worldwide. However, these novel oral anticoagulants (NOAC) pose a considerable challenge for the emergency management of acute ischemic stroke despite long-term anticoagulation. [4] [5] [6] Even without anticoagulants, intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA), the only approved therapy for ischemic stroke to date, 7, 8 increases the risk of secondary hemorrhage more than fivefold. 9 Effective longterm oral anticoagulation with vitamin K antagonists (i.e., international normalized ratio (INR) 42) increases the risk of intracerebral hemorrhage after thrombolytic therapy in patients and cerebral ischemia models. 10, 11 The risk of thrombolysis in patients with subtherapeutic warfarin use is controversial. [12] [13] [14] Current guidelines recommend excluding stroke patients with INR exceeding 1.7 from thrombolytic therapy with rtPA. 7 Anticoagulation with the NOAC was associated with significantly less primary intracerebral hemorrhagic complications compared with warfarin in clinical trials. [1] [2] [3] Because thrombolytic therapy in the event of an acute ischemic stroke was contraindicated in all trials of NOAC, data on the biologic effects of NOAC in the setting of cerebral ischemia and thrombolysis are very limited. 6, 15 Based on the lack of experience with NOAC in thrombolysis and on extrapolation from the adverse effects of warfarin, patients under effective anticoagulation with NOAC are currently excluded from systemic thrombolysis. 4, 5 So far, no data concerning the effects of thrombolysis after experimental ischemia in animals or acute ischemic stroke in patients on long-term anticoagulation with rivaroxaban have been published. 6 The purpose of the present study was to assess the effect of anticoagulation with rivaroxaban on the risk of secondary hemorrhage after intravenous thrombolysis in two well-established rodent models of ischemic stroke with reperfusion.
Solutol HS 15 (Sigma-Aldrich, Steinheim, Germany) and 50% H 2 O as described. 16 Both mice and rats received 30 mg/kg rivaroxaban via gastric gavage 1 hour before middle cerebral artery occlusion (MCAO). This dose was chosen based on a previous study showing its anticoagulatory effectiveness in vitro and its ability to enlarge collagenase-induced intracerebral hemorrhage in vivo. 17 Mice in the warfarin group received warfarin (Coumadin, Bristol-Myers-Squibb, Mü nchen, Germany) in tap water (2.5 mg warfarin dissolved in 800 mL water) over a period of 3 days resulting in a dose of B0.4 mg/kg per day. This dose produces anticoagulation with an INR target of 2 to 3 18 (see below). To eliminate effects of the vehicle solution or trauma caused by the gastric gavage, all animals in the warfarin and control groups received 10 mL/kg vehicle solution via gastric gavage 1 hour before operation.
Assessment of Coagulation Status
In the warfarin group, INR was assessed by a point-of-care coagulometer (Coaguchek XS, Roche, Penzberg, Germany) 19 before surgery to assure effective systemic anticoagulation in each individual animal (INR 2 to 3; Supplementary Information).
In separate experiments with vehicle, rivaroxaban or warfarin treatment (n ¼ 5 per group), 1 mL of citrated blood was collected by retroorbital puncture 1 hour after drug administration. INR (Innovin clotting assay, Sysmex CA-7000, Siemens Healthcare Diagnostics, Marburg, Germany) and activities of different factors (detected with reagents and BCS analyzer system from Siemens Healthcare Diagnostics, see Supplementary Information) were analyzed in the central laboratory of the University Hospital Heidelberg.
In contrast to vehicle and warfarin, the impact of rivaroxaban on in vitro coagulation is not adequately reflected by the use of INR. 20 Therefore, three additional animals per group and time point received 30 mg/kg rivaroxaban or 10 ml/kg control solution without anticoagulant. After 1, 8, 16 , and 24 hours in mice as well as 1, 4, and 8 hours in rats, 1 mL of whole blood was drawn from animals into a citrate tube. Platelet-poor plasma was obtained by immediate centrifugation at 2500 g for 15 minutes and stored at À 801C. Platelet-poor plasma samples were further examined by one investigator (SH) masked to group assignment for the determination of rivaroxaban plasma concentration and prothrombin time using Neoplastin plus reagent as previously described 17 as well as anti-factor Xa-activity (Supplementary Information).
Moreover, in vivo bleeding time was measured in five additional mice per group using a tail vein bleeding time assay. Eight hours after application of vehicle, 30 mg/kg rivaroxaban or discontinuation of warfarin with an INR of 2 to 3, respectively, mice were anaesthetized (see below). Distal 5 mm of mice tail was cut and tails were placed in 371C warm saline. Time until termination of bleeding was measured. Experiments were stopped if bleeding did not cease within 20 minutes. In rats, tail vein bleeding time was measured in control group and 1, 4, and 24 hours after administration of rivaroxaban. Distal 2 mm of rat tails was dissected and time until termination of bleeding was measured (up to 30 minutes).
Surgical Procedure in Mice
Anesthesia was induced with 4% halothane and maintained with 1% halothane (Sigma-Aldrich) in 70% N 2 O and 30% O 2 via facial mask. The middle cerebral artery was occluded by an intraluminal filament (70 fine MCAO suture, tip diameter 0.19 mm, Doccol, Redlands, CA, USA) as described 21 with some modifications. 22 Successful occlusion of the middle cerebral artery was verified by a reduction of transcranial laser Doppler signal of at least 70%. Two or three hours after MCAO, respectively, the filament was withdrawn to allow reperfusion. Recombinant tissue plasminogen activator 9 mg/kg (Actilyse, Boehringer Ingelheim, Germany) was injected 15 minutes before filament withdrawal via a tail vein catheter. Ten percent was injected as a bolus, and the remainder was infused over 30 minutes.
Surgical Procedure in Rats
Rats were pretreated with either 30 mg/kg rivaroxaban, warfarin (INR 2 to 3), or 3 ml/kg vehicle. Anesthesia was performed as described for mice. All rats underwent transient ischemia using a previously established thromboembolic model. 23 Briefly, a catheter was introduced via the external into the right internal carotid artery. Then, 12 autologous blood clots were injected. 24 Two hours after MCAO, 9 mg/kg of rtPA was injected via the femoral vein catheter (10% bolus, the remainder over 30 minutes). 22 Although spontaneous recanalization is rare in this model, it has a high rate of recanalization induced by rtPA. 24 Neurologic Score
Neurologic evaluation was performed before, 2 and 22 hours after reperfusion using a previously described neurologic score 21 with modifications. 10 
Preparation of Sections and Tissue Samples
Twenty-four hours after MCAO, animals were anesthetized and transcardially perfused with saline. Brains were immediately frozen in isopentane at À 201C and stored at À 801C. For infarct size measurement, 20-mm thick coronal cryosections were cut every 400 mm and subsequently stained with cresyl violet (Sigma-Aldrich). Infarct volume was calculated by multiplying measured areas (ImageJ, version 1.37 V, NIH, Bethesda, MD, USA) with the distance between sections and was corrected for brain edema by subtracting the volume difference of ischemic and nonischemic hemisphere from the infarct volume.
Quantification of Intracerebral Hemorrhage
Photographs (PowerShot A470, Canon, Tokyo, Japan) of unstained coronal sections were taken every 400 mm. Photographs were scored by two independent raters that were masked to group assignment. Hemorrhage score ranged from 0 to 4: 0 ¼ no hemorrhage; 1 ¼ single petechial hemorrhage, 2 ¼ confluent petechial hemorrhage, 3 ¼ a single spaceoccupying parenchymal hemorrhage encompassingo30% of infarction area, 4 ¼ multiple space-occupying parenchymal hemorrhages or single space-occupying parenchymal hemorrhage430% of infarction area (Supplementary Figure S1) .
In an additional experiment with 12 animals per group, the blood volume of the ischemic hemisphere was quantified using a previously described spectrophotometric assay 25 with modifications (Supplementary Information).
Blood-Brain Barrier Permeability for Evans Blue
To quantify postischemic blood-brain barrier (BBB) permeability, we used a previously established fluorometric assay to assess extravasation of albumin-bound Evans Blue. 26 Four additional animals per group were operated as described above with 2-hour MCAO. Animals were briefly reanesthetized 22 hours after MCAO and 1% Evans Blue in phosphatebuffered saline (80 mg/kg; Sigma-Aldrich) was injected into the femoral vein. Two hours later, mice were transcardially perfused with saline and Evans Blue content of each hemisphere was quantified using fluorometry (Supplementary Information). To demonstrate the topographical distribution of Evans Blue extravasation, two additional animals per group were operated and photographs of coronal brain sections were taken every 400 mm.
In additional experiments (n ¼ 4 per group), we examined Evans Blue extravasation after 8-hour thromboembolic ischemia in rats. Evans Blue (2% in phosphate-buffered saline, 80 mg/kg) was injected 6 hours after thromboembolic MCAO. After transcardial perfusion, 8 hours after MCAO, the fluorometric assay of Evans Blue was performed (Supplementary Information). In previous studies, BBB permeability substantially increased at 6 hours after transient MCAO and remained unchanged until 24 hours. 27, 28 Statistical Analysis Statistical analysis was performed using SPSS (Version 19, SPSS Corporation, Chicago). All values are expressed as mean ± s.d. Coagulation factor activity, INR values, infarct volume, and Evans Blue content were compared using analysis of variance with post hoc Bonferroni test. Macroscopic hemorrhage and neurologic scores were compared between groups using the non-parametric Kruskal-Wallis test and following Mann-Whitney U-test. Pearson's regression correlation was used to compare point-of-care with central lab INR, and neurologic score with infarct size. Inter-rater reliability was assessed by Cohen's Kappa. Mortality was analyzed with Pearson w 2 -test. A P value o0.05 was considered statistically significant. Figure 1A ). In the warfarin group, only mice with a central lab INR of 2.0 to 3.0 measured before MCAO were included in experiments. The target INR was reached after 3 days of pretreatment and INR remained significantly elevated for 8 hours after discontinuation of warfarin ( Figures 1B and 1D ). Rivaroxaban plasma concentration rose to 0.90 mg/L at 1 hour after administration and remained detectable for 24 hours after application ( Figure 1E ). This resulted in an anti-factor Xa activity of 96% after 1 hour and 35% after 24 hours ( Figure 1F ). Prothrombin time measurements are represented in Figure 1G .
RESULTS

Pharmacokinetics of Warfarin and Rivaroxaban in Mice
In vivo tail vein bleeding time in mice 8 hours after application of rivaroxaban or withdrawal of warfarin pretreatment was considerably increased to more than 20 minutes compared with a mean bleeding time of 1.3 ± 0.6 minutes in nonanticoagulated controls ( Figure 1C ). Table S1 ) did not differ significantly among groups in all experiments. Mortality within the first 24 hours did not differ among groups. Mortality was 7%, 13%, and 33% (protocol with 2-hour MCAO; P ¼ 0.14; Pearson's w 2 -test) and 31%, 14%, 31% (protocol with 3-hour MCAO; P ¼ 0.90), in the nonanticoagulated control, rivaroxaban and warfarin groups, respectively.
Pharmacokinetic of Warfarin and Rivaroxaban in Rats
In rats, blood pressure, heart rate, and arterial blood gases did not differ significantly between groups 10 minutes before and 2.5 hours after MCAO (Supplementary Table S2 ). Mortality in rats within the first 24 hours after MCAO as well as infarct volume did not significantly differ between groups (Supplementary Table S1 ).
Secondary Intracerebral Hemorrhage after Thrombolysis in Mice
In mice receiving thrombolysis after 2-hour MCAO with subsequent reperfusion, warfarin increased macroscopic hemorrhage on unstained coronal cryosections compared with nonanticoagulated control (mean hemorrhage score 2.1 ± 0.9 versus 1.0 ± 1.1; Po0.05; Mann-Whitney). In contrast, hemorrhage severity did not differ between mice pretreated with rivaroxaban (1.1±0.7; P40.5) and nonanticoagulated control ( Figure 2B ). There was a high interrater reliability of hemorrhage scores between the two masked raters (Cohen's Kappa ¼ 0.816; Po0.001).
Repetition of the experiment and using the spectrophotometric hemoglobin assay also revealed significantly more bleeding in mice pretreated with warfarin than in the rivaroxaban and control groups ( Figure 2D) .
We further examined secondary hemorrhage after 3-hour transient MCAO with thrombolysis. Again, the severity of secondary hemorrhage as measured by the macroscopic hemorrhage score did not differ between rivaroxaban and control (1.4±0.6 and 1.5 ± 0.7; P ¼ 0.4) but was significantly increased in animals anticoagulated with warfarin (2.3 ± 0.8; Po0.05; Figure 3B ). Interrater reliability was high (Kappa ¼ 0.86; Po0.001).
Secondary Intracerebral Hemorrhage after Thrombolysis in Rats
To increase the validity of our findings, we examined the effects of anticoagulation with rivaroxaban on secondary hemorrhage in a second species (rats) and another (thromboembolic) ischemia model. Rats in the control and rivaroxaban group had significantly lower macroscopic hemorrhage scores compared with animals pretreated with warfarin ( Figure 4 ).
Neurologic Score in Mice
The neurologic score after 24 hours correlated well with the infarct size (Pearson's r ¼ 0.74; Po0.001) but not with the hemorrhage score. There was no significant difference of the neurologic score among groups in all experiments (Supplementary Table S1 ; for 3-hours protocol with rtPA; see Figure 3C ).
Effects of Anticoagulation on Blood-Brain Barrier Permeability
In separate mice (n ¼ 4 per group), Evans Blue extravasation in the ischemic hemisphere was quantified by fluorometry. There was no difference between nonanticoagulated control (73.9 ± 109.1 ng) and mice pretreated with rivaroxaban (57.4±40.5 ng). In contrast, mice pretreated with warfarin had substantially more Evans Blue extravasate (339.3 ± 177.0 ng; Po0.05, analysis of variance). Thus, only warfarin led to a pronounced increase of postischemic BBB permeability after thrombolysis ( Figure 5B ). Evans Blue extravasation was inhomogeneous and localized within the infarct ( Figure 5C ).
In rats with thromboembolic MCAO, pretreatment with warfarin resulted in a significant increase of postischemic BBB permeability after thrombolysis compared with control, whereas Evans Blue extravasation in the rivaroxaban group did not differ from nonanticoagulated control (Supplementary Figure S4) .
DISCUSSION
Our study provides two major new findings: (1) Rivaroxaban does not increase the risk of secondary hemorrhage after thrombolysis in experimental cerebral ischemia whereas warfarin exacerbates hemorrhagic transformation. (2) Rivaroxaban in contrast to warfarin does not increase BBB permeability after ischemia and thrombolysis in mice and rats.
The present as well as previous studies have consistently demonstrated that effective anticoagulation with warfarin (i.e., INR42.0) increases secondary hemorrhage after thrombolysis in various models of focal cerebral ischemia and recanalization in mice and rats. 10, 11, 22 This is in accordance with an increased risk of hemorrhagic complications of thrombolysis in stroke patients during therapeutic anticoagulation with VKA. 12 The present study is the first to establish a model of ischemic stroke and thrombolysis during oral anticoagulation with rivaroxaban. Herein, anticoagulation with rivaroxaban does not cause an excess risk of intracranial hemorrhage after thrombolysis. Similar findings have been described for dabigatran in previous studies with 22, 29 and without thrombolysis. 30, 31 It is unlikely that the different effects of warfarin and rivaroxaban on hemorrhagic transformation after cerebral ischemia were caused by a different intensity of anticoagulation. Owing to the different modes of action, a direct comparison between both agents using the same in vitro coagulation testing is of limited value. 20 On the one hand, warfarin caused a prolonged increase of the INR and an unselective depression of the vitamin K-dependent coagulation factors II, VII, IX, X and protein C. However, we applied a very high dose of rivaroxaban resulting in peak plasma levels of 0.90 mg/L in mice. This exceeds human peak plasma levels after a once-daily dose of 20 mg rivaroxaban about threefold. 32, 33 Using the Neoplastin prothrombin time assay that is sensitive to rivaroxaban, 34 30 mg/kg rivaroxaban prolong the prothrombin time two-to threefold for at least 4 hours. 17 In the present study, rivaroxaban reduced the activity of coagulation factors II and X ( Figure 1A) . Elevated values of rivaroxaban concentration and anti-factor Xa activity remain detectable even 24 hours after rivaroxaban application ( Figures 1E and 1F) . The in vivo bleeding assay showed substantial prolongation of tail vein bleeding time even 8 hours after administration of either warfarin or rivaroxaban ( Figure 1C) . Discontinuation of anticoagulation with both rivaroxaban and warfarin results in normalization of prothrombin time and INR within 16 hours. The pretreatment for 3 days in the warfarin group were performed because of the delayed onset of action of warfarin. These findings underline that rivaroxaban also had a profound systemic anticoagulatory effect in our experiments.
Pleiotropic effects of rtPA on BBB disruption and neurovascular cell death are involved in hemorrhagic transformation of the infarct. 35 In the present study, warfarin but not rivaroxaban exacerbated BBB leakage after thrombolysis. The rather widespread effect of warfarin on multiple coagulation factors compared with the selective effect of rivaroxaban may be important for the risk and severity of brain hemorrhage. Beyond their role in the coagulation cascade, coagulation factors function as potent signaling molecules in the neurovascular unit. Reportedly, factor Xa can induce inflammatory signaling via endothelial-based proteaseactivated receptors 1 and 2, thereby increasing endothelial permeability. 36, 37 Rivaroxaban can attenuate this inflammatory process in cultured human atrial cells. 38 On the contrary, the vitamin K-dependent factors-activated protein C and Factor VII have protective effects on the BBB, which are mediated by the activation of the endothelial protein C receptor and downregulation of matrix metalloproteinases. 39, 40 The activity of both factors was substantially reduced by warfarin but not by rivaroxaban in the present study. Activated protein C can reduce rtPA-induced secondary hemorrhage as well as infarct size in mice. 41 Whether these mechanisms underlie the different effect of warfarin and rivaroxaban on secondary intracerebral hemorrhage remains to be elucidated.
Clinicians will be confronted with an increasing number of patients suffering a stroke despite anticoagulation with rivaroxaban. 4, 6 Although present and previous data justify withholding thrombolytic treatment in patients with warfarin in the therapeutic INR range, our findings may suggest that hemorrhagic adverse events do not occur more frequently in patients anticoagulated with rivaroxaban than in nonanticoagulated stroke patients. Interestingly, high doses of rivaroxaban 17 and dabigatran 42 are necessary to increase intracerebral hemorrhage volume in murine intracerebral hemorrhage that is induced by striatal collagenase injection. In contrast, the same high dose (30 mg/kg) of rivaroxaban did not cause excess secondary hemorrhagic transformation after thrombolysis in the present study. Although the underlying molecular mechanisms remain to be elucidated, these data indicate a lower risk of intracranial hemorrhagic complications of new OAC compared with warfarin. Nevertheless, no clinical experience with thrombolysis in rivaroxaban-treated patients has been reported in the literature so far. Thus, we caution against the uncritical transfer of our experimental findings into clinical practice.
Our study has strengths and limitations. Middle cerebral artery occlusion in all experiments caused extensive infarction in the middle cerebral artery territory. Thus, our experiments were designed to predispose the animals to additional hemorrhage due to anticoagulation. Our findings were robust and independent of species (mouse, rat), experimental paradigm (filament versus thromboembolic MCAO), and timing of recanalization (2 versus. 3 hours). A limitation of our study is that only young rodents without significant comorbidities were studied. The different anticoagulation protocol was chosen because of the delayed onset of the anticoagulatory effect of warfarin. In contrast, there is a rapid onset of therapeutic action of rivaroxaban in mice 17 and man 33 with high plasma concentrations and a prolongation of prothrombin time already 1 hour after oral application.
In conclusion, the present study suggests that pretreatment with rivaroxaban does not increase the risk of secondary hemorrhage after thrombolysis in ischemic stroke. Warfarin and rivaroxaban have profoundly different effects on postischemic blood-brain barrier damage. Cautious evaluation of our findings in the clinical setting is warranted.
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